Physician profile
Anne Painter
NPI 1174971253
$1,334.86
in general payments reported to CMS, 2019-2025
19 companies · $427 in 2025
The $427 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.12 · 2023: $156 · 2024: $740 · 2025: $427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,153 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,152.76 |
| Education | $169.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $226.70 | 2023-2024 | |
| Astellas Pharma US INC | $199.72 | 2024 | Cresemba |
| Aimmune Therapeutics, INC. | $138.38 | 2025 | Zenpep |
| Janssen Biotech, INC. | $134.66 | 2023-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $129.53 | 2024-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $95.96 | 2024-2025 | Entyvio |
| Pfizer INC. | $73.58 | 2024 | |
| Genzyme Corporation | $73.15 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $53.93 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $36.93 | 2024 | Resmetirom |
| Merck Sharp & Dohme LLC | $27.23 | 2025 | Capvaxive, Pifeltro |
| Sandoz INC. | $25.94 | 2024 | Hyrimoz |
| Ferring Pharmaceuticals INC. | $23.53 | 2024 | Rebyota |
| Novo Nordisk INC | $18.85 | 2025 | Wegovy |
| Regeneron Healthcare Solutions, INC. | $17.44 | 2025 | Dupixent |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $17.00 | 2024 | |
| Lilly USA, LLC | $15.79 | 2024 | Omvoh |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.42 | 2023 | Cyltezo |
| Paratek Pharmaceuticals, INC. | $12.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Painter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.